University of California

City of Hope

Leland Stanford Junior University

Anna M Wu

Robert E Reiter

Andrew A Raubitschek

Mark A Sherman

Jonathan Braun

Lynn K Gordon

Sanjiv Sam Gambhir

John E Shively

Andreas M Loening

Madhuri Wadehra

Kathy A Kelly

Tove Olafsen

Kaori Shimazaki Dadgostar

Eric J Lepin

James David Marks

Yu Zhou

Kathleen A Kelly

Paul J Yazaki

Michael C Jensen

Kaori Shimazaki

Kaori Shimizaki

Madhuri Wadegra-Dhawan

Keyu Li

Bhaswati Barat

Human antibody fragments against c-Met have been identified through phage display technology. The high affinity and low immunogenicity make them very useful for both in vivo and in vitro applications. These novel human antibodies can greatly help the study of drug resistance in EGFR targeted therapies, and improve the diagnosis and treatment of cancer patients.

Fully human antibodies and fragments recognizing human c-Met

The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.

Covalent disulfide-linked diabodies and uses thereof

The present invention provides methods and compositions useful in the treatment or prevention ofinfections and cancer. The methods and compositions inhibit the entry ofinto a host cell expressing EMP2 by interfering with the interaction between theand EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.

Antibodies which bind to epithelial membrane protein 2 (EMP2)

The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The Present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.

High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection

Methods of treating cancer by administering EMP2 antibodies

The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.

Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting

The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.

EMP2 antibodies and methods of use thereof for causing regression of a solid tumor or symptoms thereof

EMP2 antibodies and methods of use thereof causing regression of a solid tumor or symptoms thereof

The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.

Fully human antibodies against N-cadherin

Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.

Humanized anti-prostate stem cell antigen monoclonal antibody

Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.

Luciferases and methods for making and using the same

EMP2 antibodies and their therapeutic uses

Briefly described, embodiments of this disclosure include polynucleotides that encode mutantluciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.

Growing community of inventors

Sherman Oaks, CA, United States of America

Anna M Wu